15,203 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Purchased by Brophy Wealth Management LLC

Brophy Wealth Management LLC purchased a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 15,203 shares of the biopharmaceutical company’s stock, valued at approximately $1,275,000.

Other hedge funds have also made changes to their positions in the company. M&T Bank Corp increased its stake in Gilead Sciences by 3.2% during the third quarter. M&T Bank Corp now owns 192,952 shares of the biopharmaceutical company’s stock worth $16,177,000 after acquiring an additional 5,943 shares during the last quarter. Executive Wealth Management LLC purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $222,000. LRI Investments LLC grew its holdings in shares of Gilead Sciences by 289.9% during the 3rd quarter. LRI Investments LLC now owns 811 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 603 shares during the period. Geller Advisors LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth about $216,000. Finally, Hamilton Capital LLC raised its holdings in Gilead Sciences by 5.7% in the 3rd quarter. Hamilton Capital LLC now owns 4,224 shares of the biopharmaceutical company’s stock valued at $375,000 after buying an additional 229 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the sale, the chief financial officer now directly owns 138,919 shares in the company, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 476,591 shares of company stock valued at $43,747,615 over the last three months. 0.29% of the stock is currently owned by insiders.

Gilead Sciences Price Performance

Shares of NASDAQ GILD opened at $90.59 on Tuesday. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company’s 50-day moving average price is $89.33 and its 200 day moving average price is $78.89. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $98.90. The stock has a market cap of $112.90 billion, a price-to-earnings ratio of 1,006.56, a PEG ratio of 2.86 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. During the same quarter in the prior year, the firm earned $2.29 earnings per share. The company’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, research analysts forecast that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 3.40%. The ex-dividend date is Friday, December 13th. Gilead Sciences’s payout ratio is 3,422.22%.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Piper Sandler increased their target price on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “overweight” rating in a report on Thursday, November 7th. Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Sanford C. Bernstein began coverage on Gilead Sciences in a research note on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price for the company. Finally, Robert W. Baird increased their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Twelve analysts have rated the stock with a hold rating, eleven have given a buy rating and four have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $95.41.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.